Q3 2024 EPS Estimates for FibroGen, Inc. (NASDAQ:FGEN) Cut by William Blair

FibroGen, Inc. (NASDAQ:FGEN) – Analysts at William Blair lowered their Q3 2024 earnings per share (EPS) estimates for shares of FibroGen in a note issued to investors on Wednesday, August 7th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.23) per share for the quarter, down from their previous estimate of ($0.16). William Blair has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($1.05) per share. William Blair also issued estimates for FibroGen’s Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at $0.05 EPS and FY2025 earnings at $0.24 EPS.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same quarter in the prior year, the company posted ($0.65) earnings per share.

Separately, StockNews.com began coverage on shares of FibroGen in a report on Saturday. They issued a “hold” rating for the company.

FibroGen Trading Down 7.2 %

Shares of NASDAQ FGEN opened at $0.41 on Friday. FibroGen has a 12-month low of $0.33 and a 12-month high of $2.93. The stock has a market cap of $40.68 million, a P/E ratio of -0.17 and a beta of 0.71. The business’s fifty day simple moving average is $0.96 and its 200-day simple moving average is $1.42.

Insiders Place Their Bets

In other news, insider Deyaa Adib bought 22,123 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was acquired at an average price of $1.17 per share, for a total transaction of $25,883.91. Following the acquisition, the insider now owns 82,123 shares of the company’s stock, valued at $96,083.91. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On FibroGen

Large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC increased its position in shares of FibroGen by 23.7% in the 4th quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock worth $8,654,000 after purchasing an additional 1,872,000 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares during the period. Pennant Investors LP acquired a new stake in shares of FibroGen in the 4th quarter worth about $681,000. Lighthouse Investment Partners LLC bought a new stake in shares of FibroGen during the fourth quarter valued at approximately $136,000. Finally, Franklin Street Advisors Inc. NC bought a new stake in FibroGen during the 2nd quarter valued at $89,000. 72.71% of the stock is owned by institutional investors and hedge funds.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.